TRCT
SER icon

Tower Research Capital (TRC)’s Serina Therapeutics SER Stock Holding History

Tower Research Capital (TRC)’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99K Buy
2,570
+1,727
+205% +$3.24K ﹤0.01% 4320
2026
Q1 		$1.64K Buy
843
+394
+88% +$867 ﹤0.01% 4626
2025
Q4 		$859 Buy
449
+286
+175% +$1.16K ﹤0.01% 4803
2025
Q3 		$874 Buy
+163
New +$868 ﹤0.01% 4918
2025
Q2 		– Sell
-912
Closed -$5.17K – 5627
2025
Q1 		$5.17K Sell
912
-97
-10% -$459 ﹤0.01% 4149
2024
Q4 		$5.05K Buy
1,009
+205
+25% +$1.21K ﹤0.01% 4357
2024
Q3 		$5.38K Sell
804
-1,151
-59% -$9.13K ﹤0.01% 4285
2024
Q2 		$18.7K Buy
1,955
+1,507
+336% +$14.8K ﹤0.01% 3790
2024
Q1 		$6.03K Buy
448
+143
+47% +$2K ﹤0.01% 4448
2023
Q4 		$4.13K Sell
305
-70
-19% -$1.29K ﹤0.01% 4989
2023
Q3 		$8.97K Buy
375
+46
+14% +$1.22K ﹤0.01% 4283
2023
Q2 		$10.3K Sell
329
-56
-15% -$1.2K ﹤0.01% 4134
2023
Q1 		$9K Sell
385
-92
-19% -$2.11K ﹤0.01% 4556
2022
Q4 		$9K Buy
477
+132
+38% +$2.78K ﹤0.01% 4290
2022
Q3 		$7K Buy
345
+68
+25% +$1.54K ﹤0.01% 4942
2022
Q2 		$6K Buy
277
+102
+58% +$2.75K ﹤0.01% 4967
2022
Q1 		$5K Buy
175
+132
+307% +$3.76K ﹤0.01% 5123
2021
Q4 		$2K Hold
43
– – ﹤0.01% 5687
2021
Q3 		$1K Sell
43
-56
-57% -$2.35K ﹤0.01% 5552
2021
Q2 		$5K Buy
99
+56
+130% +$2.81K ﹤0.01% 4746
2021
Q1 		$2K Sell
43
-479
-92% -$33.5K ﹤0.01% 5063
2020
Q4 		$28K Buy
522
+479
+1,114% +$27.6K ﹤0.01% 3633
2020
Q3 		$1K Sell
43
-174
-80% -$6.21K ﹤0.01% 4743
2020
Q2 		$7K Buy
217
+174
+405% +$5.12K ﹤0.01% 4177
2020
Q1 		$1K Hold
43
– – ﹤0.01% 2865
2019
Q4 		$3K Buy
43
+12
+39% +$648 ﹤0.01% 2981
2019
Q3 		$2K Buy
31
+19
+158% +$1.8K ﹤0.01% 3753
2019
Q2 		$2K Sell
12
-164
-93% -$22.2K ﹤0.01% 3332
2019
Q1 		$26K Buy
176
+123
+232% +$18K ﹤0.01% 2133
2018
Q4 		$6K Buy
+53
New +$6.74K ﹤0.01% 2824

Other funds holding SER

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AWE
Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return

Tower Research Capital (TRC)'s SER Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Serina Therapeutics (SER) stake by 205% in Q2 2026, buying an estimated $3.24K and bringing the position to 2,570 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #4320.

Tower Research Capital (TRC) first reported a position in SER in Q4 2018 and has held it in 30 quarters since. The position peaked at $28K in Q4 2020. 21 funds tracked by Wall St. Rank hold SER as of Q2 2026.

  • Tower Research Capital (TRC) held 2,570 shares of Serina Therapeutics worth $4.99K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,727 Serina Therapeutics shares in Q2 2026, an estimated $3.24K.
  • Serina Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4320 holding.
  • Tower Research Capital (TRC) first reported a position in Serina Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Tower Research Capital (TRC)'s Serina Therapeutics position peaked at $28K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.